Clinical evaluation of Nisha Amalaki and Chandraprabha Vati in the management of Type II Diabetes Mellitus (Madhumeha) - Clinical evaluation of Nisha Amalaki and Chandraprabha Vati in the management of Type II Diabetes Mellitus (Madhumeha)

Central Council For Research in Ayurvedic Sciences0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Diabetics aged between 30 to 60 years who are on Lifestyle modification &/or on Tab. Metformin upto 2 gm / day.
•2.Patients who are diagnosed to be Type 2 Diabetics by either having Glycosylated haemoglobin (HbA1c) >= 6.5% or BS-F > 126 mg% or BS-PP >200 mg%.
•3.Willing to participate.

•1.Patients already diagnosed to be suffering from the complications of Diabetes Mellitus viz., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, etc.
•2.Patients suffering from Type 1 Diabetes mellitus or brittle diabetes mellitus.
•3.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•4.Hypertensive patients ( > 140 / 90 mm Hg).
•5.Patients with poorly controlled Glycemic status (HbA1c >8%).
•6.Symptomatic patient with clinical evidence of Heart failure.
•7.Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2 mg/dl),uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease.
•8.Pregnant / Lactating women.
•9.Patient on steroids, oral contraceptive pills or estrogen replacement therapy.
•10.Alcoholics and/or drug abusers.
•11.Patients with evidence of malignancy
•12.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.)
•13.H/o hypersensitivity to any of the trial drugs or their ingredients.
•14.Patients who have completed participation in any other clinical trial during the past six (06) months.
•15.Any other condition which the Investigator thinks may jeopardize the study.

发起方